AU Patent

AU2020397176A1 — Methods and compositions for treating edema refractory to oral diuretics

Assigned to RESQ Pharmaceuticals LLC · Expires 2022-06-30 · 4y expired

What this patent protects

The present invention features methods and compositions for the intranasal, sublingual, and subcutaneous administration of bumetanide for the treatment of subjects suffering from edema refractory to oral diuretics.

USPTO Abstract

The present invention features methods and compositions for the intranasal, sublingual, and subcutaneous administration of bumetanide for the treatment of subjects suffering from edema refractory to oral diuretics.

Drugs covered by this patent

Patent Metadata

Patent number
AU2020397176A1
Jurisdiction
AU
Classification
—
Expires
2022-06-30
Drug substance claim
No
Drug product claim
No
Assignee
RESQ Pharmaceuticals LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.